Clinical Trial Update: Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sapanisertib in adults with relapsed or refractory acute lymphoblastic leukemia; results were posted in May 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Sapanisertib (sapanisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Status: COMPLETED | Results posted: 2022-05-24